Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06321250 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

StatusRecruiting
PhasePhase 1
SponsorJemincare
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 9, 2024 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 28, 2024 to Mar 14, 2024
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Jemincare
23 trials monitored
See all monitored trials
Kidney Cancer
889 trials monitored
See 68 trials at risk
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.
Trial Details
NCT Number NCT06321250
Lead Sponsor Jemincare
Collaborators: Zhejiang Hangyu Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Renal Cell Carcinoma Metastatic
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov